ClinicalTrials.gg
CompletedNCT00691483Updated Nov 20, 2015Results posted

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

A Phase 4 interventional study of placebo and varenicline in Smoking Cessation, sponsored by Pfizer. Completed at 33 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-20.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
659
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
17th of 110
659 · median 209
Started
2008
with 13 others
Phase 4
47 of 110
3 open now
Registered
26th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 17th largest by enrollment, is one of 14 that started in 2008, is one of 47 in phase 4, and was the 26th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • smoking cessation
  • smoking treatment
  • patient self-selected quit date
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • 18 to 75 yrs old
  • Motivated to stop smoking
  • Smoke at least 10 cigarettes/day

Exclusion criteria

Exclusion Criteria:

  • Active psychiatric disease
  • Severe or unstable cardiovascular or pulmonary disease
  • Current or recent treatment to stop smoking
  • Previous use of varenicline
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
659 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    varenicline

    Drug: varenicline

Interventions

  • Drugplacebo

    placebo tablet taken orally twice daily for 12 weeks

  • varenicline tablets, 1 mg taken orally twice daily for 12 weeks

    Also known as: Chantix, Champix

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With 4-week Continuous Abstinence (CA)

    The percentage of participants who reported complete abstinence from cigarette smoking and other nicotine use (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \>10 parts per million (ppm) at any visits Week 9 through Week 12. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.

    Time frame: Week 9 through Week 12

Secondary outcomes

  1. Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24

    Percentage of participants with CA from cigarette smoking and other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use, who did not have CO \>10 ppm at any visits Week 9 through Week 24. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.

    Time frame: Week 9 through Week 24

  2. Percentage of Participants With Long Term Quit Through Week 24

    Responder for the primary endpoint of CA from Week 9 through Week 12 and who had no more than 6 days of smoking during the non-treatment phase of the study. For Weeks 13, 16, 20, and 24, long term quit was determined by CO-confirmed in-clinic visit.

    Time frame: Week 9 through Week 24

  3. Percentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)

    Percentage of participants with complete abstinence from cigarette smoking or other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use for the 7 days prior to Week 12 and Week 24, respectively, who did not have CO \>10 ppm at any visits. CO-confirmed in-clinic visit.

    Time frame: Week 12 and Week 24

  4. Percentage of Participants With 4-week Point Prevalence of Nonsmoking

    Percentage of participants with complete abstinence from cigarette smoking or use of tobacco products for the 4 weeks prior to Week 24 who did not have CO \>10 ppm at any visits.

    Time frame: Week 24

Other outcomes

  1. Change From Baseline in Fagerström Test for Nicotine Dependence (FTND) to Day of First Quit Attempt (FQA) Through Week 5 by Smoking Status at Weeks 9-12

    Change in nicotine dependence from baseline to the date of the FQA within the first 5 weeks. FTND was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The FTND contains 4 yes-no and 2 multiple choice questions and can be used in a self-report format. The items on FTND are scored 0 to 3 for multiple choice items, the items are summed to yield a total score of 0-10 (0=minimum nicotine dependence; 10=maximum nicotine dependence).

    Time frame: Baseline through Week 5

07

Results

Posted Sep 30, 2010

Participant flow

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started493166
Received treatment486165
Completed425141
Not completed6825
Withdrew: Adverse event146
Withdrew: Lost to follow-up1710
Withdrew: Withdrawal by subject247
Withdrew: Other known cause61
Withdrew: Randomized by not treated71

Outcome measures

PrimaryPercentage of Participants With 4-week Continuous Abstinence (CA)

The percentage of participants who reported complete abstinence from cigarette smoking and other nicotine use (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \>10 parts per million (ppm) at any visits Week 9 through Week 12. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.

Time frame:
Week 9 through Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-week Continuous Abstinence (CA)
Percentage of participantsVareniclinePlacebo
Percentage of Participants With 4-week Continuous Abstinence (CA)53.919.4
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (To preserve the type I family-wise error rate of 0.05, a step-down procedure to be used for the analysis of CA for Week 9 through Week 12 and the CA for Week 9 through Week 24.) · Odds ratio (or): 6.03 · 95% CI 3.80 to 9.56Model to include the main effects of treatment and pooled center.
SecondaryPercentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24

Percentage of participants with CA from cigarette smoking and other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use, who did not have CO \>10 ppm at any visits Week 9 through Week 24. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.

Time frame:
Week 9 through Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24
Percentage of participantsVareniclinePlacebo
Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-2435.212.7
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (To preserve the type I family-wise error rate of 0.05, a step-down procedure to be used for the analysis of CA for Week 9 through Week 12 and the CA for Week 9 through Week 24.) · Odds ratio (or): 4.45 · 95% CI 2.62 to 7.55Model to include the main effects of treatment and pooled center.
SecondaryPercentage of Participants With Long Term Quit Through Week 24

Responder for the primary endpoint of CA from Week 9 through Week 12 and who had no more than 6 days of smoking during the non-treatment phase of the study. For Weeks 13, 16, 20, and 24, long term quit was determined by CO-confirmed in-clinic visit.

Time frame:
Week 9 through Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Long Term Quit Through Week 24
Percentage of participantsVareniclinePlacebo
Percentage of Participants With Long Term Quit Through Week 2440.714.6
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (A 0.05 level of significance without adjustment for multiplicity.) · Odds ratio (or): 4.91 · 95% CI 2.96 to 8.13Model to include the main effects of treatment and pooled center.
SecondaryPercentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)

Percentage of participants with complete abstinence from cigarette smoking or other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use for the 7 days prior to Week 12 and Week 24, respectively, who did not have CO \>10 ppm at any visits. CO-confirmed in-clinic visit.

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)
Percentage of participantsVareniclinePlacebo
Week 1259.524.2
Week 2443.017.6
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (A 0.05 level of significance without adjustment for multiplicity.) · Odds ratio (or): 5.66 · 95% CI 3.66 to 8.75Model to include the main effects of treatment and pooled center.
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (A 0.05 level of significance without adjustment for multiplicity.) · Odds ratio (or): 4.12 · 95% CI 2.58 to 6.58Model to include the main effects of treatment and pooled center.
SecondaryPercentage of Participants With 4-week Point Prevalence of Nonsmoking

Percentage of participants with complete abstinence from cigarette smoking or use of tobacco products for the 4 weeks prior to Week 24 who did not have CO \>10 ppm at any visits.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-week Point Prevalence of Nonsmoking
Percentage of participantsVareniclinePlacebo
Percentage of Participants With 4-week Point Prevalence of Nonsmoking42.017.0
Statistical analysis
  • Varenicline vs Placebo · Regression, Logistic · p = <0.0001 (A 0.05 level of significance without adjustment for multiplicity.) · Odds ratio (or): 4.14 · 95% CI 2.58 to 6.67Model to include the main effects of treatment and pooled center.
Other pre-specifiedChange From Baseline in Fagerström Test for Nicotine Dependence (FTND) to Day of First Quit Attempt (FQA) Through Week 5 by Smoking Status at Weeks 9-12

Change in nicotine dependence from baseline to the date of the FQA within the first 5 weeks. FTND was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The FTND contains 4 yes-no and 2 multiple choice questions and can be used in a self-report format. The items on FTND are scored 0 to 3 for multiple choice items, the items are summed to yield a total score of 0-10 (0=minimum nicotine dependence; 10=maximum nicotine dependence).

Time frame:
Baseline through Week 5
Reported as:
Mean · Units on a scale
Change From Baseline in Fagerström Test for Nicotine Dependence (FTND) to Day of First Quit Attempt (FQA) Through Week 5 by Smoking Status at Weeks 9-12
Units on a scaleVareniclinePlacebo
Responders-2.3 ± 2.53-1.8 ± 1.95
Non-Responders-2.5 ± 2.55-1.8 ± 2.13

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—6/486 (1.2%)297/486 (61.1%)
Placebo—1/165 (0.6%)79/165 (47.9%)
Most frequent serious events
Most frequent serious events
EventVareniclinePlacebo
Suicidal ideationPsychiatric disorders0/4861/165
Intervertebral disc protrustionMusculoskeletal and connective tissue disorders2/4860/165
Carotid artery stenosisNervous system disorders1/4860/165
SyncopeNervous system disorders1/4860/165
Calculus uretericRenal and urinary disorders1/4860/165
PyelocaliectasisRenal and urinary disorders1/4860/165
Ureteric obstructionRenal and urinary disorders1/4860/165
Peripheral arterial occlusive diseaseVascular disorders1/4860/165
Most frequent other events
Showing 10 of 32
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders142/48615/165
Abnormal dreamsPsychiatric disorders61/4865/165
HeadacheNervous system disorders55/48620/165
InsomniaPsychiatric disorders43/4866/165
NasopharyngitisInfections and infestations34/48614/165
DizzinessNervous system disorders8/4868/165
ConstipationGastrointestinal disorders23/4865/165
FatigueGeneral disorders23/4863/165
Sleep disorderPsychiatric disorders20/4866/165
VomitingGastrointestinal disorders19/4861/165

Baseline characteristics

Age, Customized
Age, Customized(Participants)VareniclinePlaceboTotal
Between 18 and 44 years24893341
Between 45 and 64 years20964273
>= 65 years29837
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female19366259
Male29399392
08

Study locations

33 sites
  • Pfizer Investigational Site
    Litchfield Park, Arizona 85340, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    Santa Ana, California 92705, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40509, United States
  • Pfizer Investigational Site
    Milford, Massachusetts 01757, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68116-2004, United States
  • Pfizer Investigational Site
    Endwell, New York 13760, United States
  • Pfizer Investigational Site
    Bridgeville, Pennsylvania 15017, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19146, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Buenos Aires, C1405BCH, Argentina
  • Pfizer Investigational Site
    Santo André, SP 09060-650, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T1Y 6J4, Canada
  • Pfizer Investigational Site
    Quebec, G1V 4M6, Canada
  • Pfizer Investigational Site
    Shenyang, Liaoning 110016, China
  • Pfizer Investigational Site
    Beijing, 100020, China
  • Pfizer Investigational Site
    Guangzhou, 510120, China
  • Pfizer Investigational Site
    Brno, 656 91, Czech Republic
  • Pfizer Investigational Site
    Praha 2, 120 00, Czech Republic
  • Pfizer Investigational Site
    Caen, 14033, France
  • Pfizer Investigational Site
    Berlin, 10787, Germany
  • Pfizer Investigational Site
    Goettingen, 37075, Germany
  • Pfizer Investigational Site
    Budapest, 1525, Hungary
  • Pfizer Investigational Site
    Debrecen, 4012, Hungary
  • Pfizer Investigational Site
    Pisa, 56124, Italy
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Monterrey, Nuevo Leon 64460, Mexico
  • Pfizer Investigational Site
    Gwei Shan Township, Taoyuan County, 333, Taiwan
  • Pfizer Investigational Site
    Kaohsiung, 813, Taiwan
  • Pfizer Investigational Site
    London, SW18 4DD, United Kingdom
09

References and documents

Publications

  • Hughes JR, Russ C, Messig MA. Association of deferring a quit attempt with smoking cessation success: a secondary analysis. J Subst Abuse Treat. 2014 Feb;46(2):264-7. doi: 10.1016/j.jsat.2013.08.015. Epub 2013 Sep 24. PubMed 24074849 ↗
  • Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, St Aubin LB, Russ C; Flexible Quit Date Study Group. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012 Mar;14(3):343-50. doi: 10.1093/ntr/ntr220. Epub 2011 Nov 11. PubMed 22080588 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Sep 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2008
First posted
Jun 5, 2008
Start
Sep 2008
Primary completionActual
Sep 2009
CompletionActual
Dec 2009
Results first posted
Sep 30, 2010
Last update
Nov 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00691483
Lead sponsor
Pfizer
First posted
Jun 5, 2008
Start date
Sep 2008
Primary completion
Sep 2009
Completion
Dec 2009
Results posted
Sep 30, 2010
Last update
Nov 20, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion